Name : Biotinylated Human B7-H4 Protein
Product Source :
Recombinant Biotinylated Human B7-H4 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Phe29-Ala258.[Accession | Q7Z7D3-1]
Molecular Weight :
The protein has a predicted MW of 28.2 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Biotinylated Human B7-H4 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Biotinylated Human B7-H4 is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized Biotinylated Human B7-H4, His Tag at 2μg/ml (100μl/Well) on streptavidin(5μg/ml) precoated plate. Dose response curve for Anti-B7-H4 Antibody, hFc Tag with the EC50 of 4.9ng/ml determined by ELISA.
Background :
B7-H4, also known as B7x and B7S1, is a 50-80 kDa glycosylated member of the B7 family of immunomodulatory proteins.B7-H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis. A soluble form of B7-H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status.
Synonyms :
B7H4; B7-H4; B7S1; B7h.5; B7x; FLJ22418; VTCN1; PRO1291
References & Citations :
(1)Smith J B, Caitlin S, Powell D J. B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look[J]. Gynecologic Oncology, 2014, 134(1):181-189.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
DMBT1 Proteinweb
ITGBL1 ProteinFormulation
Popular categories:
GP-Ib alpha/CD42b
CLEC2D